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Abstract
Background Ciliopathies are a group of diseases associated with abnormal structure or function of primary cilia. Ciliopathies include
polycystic kidney disease (PKD), a pathology associated with vascular hypertension. We previously showed that cilia length regulates cilia
function, and cilia function is required for nitric oxide (NO) biosynthesis in endothelial cells. Because patients with PKD show abnormal
sensory cilia function, the aim of our current study was to search for a targeted therapy focused on primary cilia, which we refer to as ‘ciliotherapy’. Methods and Results In the present studies, our in vitro analyses refined fenoldopam as an equipotent and more specific dopaminergic agonist to regulate cilia length and function. Our in vivo studies indicated that fenoldopam increased cilia length and serum NO
thereby reducing blood pressure in a PKD mouse model. Our crossover, multicenter, double-blind and placebo-controlled clinical study further indicated that cilia-targeting therapy showed an overall reduction in mean arterial pressure in PKD patients. Conclusions Overall, our
studies provide the first evidence of ciliotherapy as an innovative intervention in patients with abnormal primary cilia.
J Geriatr Cardiol 2014; 11: 63−73. doi: 10.3969/j.issn.1671-5411.2014.01.001
Keywords: Primary cilium; Blood pressure; Mechanosensor; Mechanotransduction; Chemosensor; Fluid-shear stress

1 Introduction
Polycystic kidney disease (PKD) is the most common
life-threatening hereditary genetic disease, compared to the
combined numbers of individuals affected by cystic fibrosis,
Downs syndrome, hemophilia, muscular dystrophy, and
sickle cell anemia. One of the most concerning issues in
PKD is vascular hypertension. In particular, hypertension
occurs early in PKD compared to the general population.[1]
Although it has been known that PKD is caused by dysfunction in mechanosensory primary cilia,[2,3] there is unfortunately no targeted therapy on primary cilia at present.
It has been shown that cilia function can be regulated by
cilia length.[4] Furthermore, vascular endothelia require
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proper cilia function for nitric oxide (NO) biosynthesis, in
which primary cilia act as molecular switches to initiate NO
biochemical reaction.[5,6] More importantly, vascular endothelia obtained from patients with PKD show abnormal
sensory cilia function.[5,7] Based on our previous drug
screening that dopamine enhances cilia function by extending the length of cilia,[8] the aim of our current study was
therefore to search for a targeted therapy focused on primary cilia.

2 Methods
The use of animal cells or tissues was approved by the
Animal Care and Use Committee of The University of
Toledo. The title of our animal cell protocol was Molecular
Biology of Kidney Diseases (No. N-105587), and it was
approved on June 2010. Signed and informed consent to
participate in our clinical study was obtained from the patients, and our clinical protocols were approved by the Department for Human Research Protections of the Biomedical Institutional Review Board of the University of Baghdad,
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College of Pharmacy. Our clinical protocols were also
posted publicly and approved by the International Clinical
Trials Registry Platform of the World Health Organization.
The clinical trial registry number was IRCT2012110611384N1.
The title of our clinical protocols was Dopamine Receptor
in Hypertension with Polycystic Kidney Disease (No.
DR-PKD), and it was approved on May 2012. The study
participants were recruited in June 1 of 2012, and the study
was completed in September 30 of 2012.
2.1 Cell culture
Mouse endothelial cells were previously generated and
characterized in our laboratory.[6] Cells were grown in Dulbecco’s Modification of Eagle's Media (Cellgro, Inc.) containing 10% fetal bovine serum and 1% penicillin G plus
streptomycin sulfate (HyClone, Inc.) at 39°C for 3–5 days
until fully differentiated before analysis.
2.2 Endothelial-specific Pkd1 mouse model
Endothelial specific-Cre mice were purchased from
German Cancer Research Center (DKFZ) in 2009. These
mice were bred with Pkd1flox/flox, as previously described.[9]
Only male mice in Balb/C background after backcross of 15
generations were used to reduce complexity in hormonal
regulation of blood pressure or genetic background, although female mice shared the same blood pressure as in
males (data not shown). The endothelial-specific Cre mice
were confirmed with a ROSA model, purchased from the
Jackson Laboratory in Maine (Stock Number: 007576). To
induce Cre recombinant and thus a gene knockout, oneweek old pups were injected intra-peritoneally with 250 μg
of 50 μL tamoxifen every day for five consecutive days.
Blood pressure reading was taken two weeks later.
2.3 Blood pressure measurement
After inactivation of Pkd1 in Tie2Cre:Pkd1flox/flox at oneweek old, blood pressure was taken from three-week old
mice showing no apparent renal cyst formation. Blood
pressure was measured in conscious, trained mice at room
temperature using a non-invasive blood pressure system
tail-cuff monitor and a built-in photoelectric sensor (Visitech System, NC). Blood pressure measurements were
taken twice daily for the duration of the study after the initial three days acclimating each mouse to the cuff. The data
from the tail cuff method was also verified with a more invasive, surgically implanted telemetry probe (data not
shown). Per previous literature,[10] our initial dosage of fenoldopam was 2 mg/kg per day; we also tried 1 mg/kg which
provided us with a less consistent result (data not shown).
The dosage of 1.5 mg/kg per day was finally used as it was

sufficient to lower the blood pressure consistently in Pkd1
mice. The 1.5 mg/kg of fenoldopam was slowly administered for 20–30 min duration intravenously every day for
the duration of our study. All measurements were performed
by two-blinded operators.
2.4 NO measurement
A non-fluorescent, CO2-independent medium for imaging was used (pH 7.4). This medium contained (in mmol/L)
CaCl2 1.26, MgSO4 0.81, KCl 5.4, KH2PO4 0.44, NaCl 137,
Na2HPO4 0.34, NaHCO3 4.166 and D-glucose 5.6. After
incubation with the NO-sensitive probe 4-amino-5-methylamino-2',7'-difluorofluorescein (DAF-FM, 20 μmol/L; Invitrogen, Inc.) for 30 min at 39°C, cells were washed to remove excess probe. DAF-FM images were captured at excitation and emission wavelengths of 495 and 515 nm every
5 s through a Nikon TE2000 microscope equipped with a
Coolsnap EZ cooled charge-coupled device monochrome
digital camera using Metamorph software (Molecular Devices, Corp.). In some cases, serum NO was measured with
nitrate/nitrite fluoremetric assay kit (Cayman Chemical,
Corp.) as described previously.[5]
2.5 Immunofluorescence
For cilia length studies, endothelial cells were incubated
with fenoldopam (Hospira, Inc.) at 0, 1.0, 10.0, 20.0 and
50.0 μmol/L for 16 h at 39°C. Changes in the cilia length in
the endothelial cells of femoral arteries were also measured
and compared to age-matched control groups. Cells and
tissues were fixed as described previously.[8] Anti-acetylated
α-tubulin antibody (1: 10,000 dilution; clone 6-11B-1;
Sigma, Inc.), fluorescein isothiocyanate (FITC)-labeled anti-mouse antibody (1: 500 dilution; Vector Lab, Inc.), and
4′,6-diamidino-2-phenylindol (DAPI, Vector Lab, Inc.)
were used. All measurements and analyses were performed
by two-blinded operators.
2.6 Cilia function analysis
For fluid-shear stress experiments, cells grown on glassbottom plates were installed in custom-made apparatus
measured 3 cm × 2.5 mm connected with 2 pumps (Instech,
Corp.), one pump for inward fluid flow from a reservoir to
the cells and the other for outward fluid flow from the cells
to the reservoir, as previously described.[5] For dopamine
receptor-5 (DR5) agonist experiments, cells were challenged with dopamine (10 μmol/L; Sigma, Inc.) or fenoldopam (10 μmol/L; Hospira, Inc.). In some experiments, cells
were incubated with fenoldopam (10 μmol/L) for 16 h at
39°C before shear stress experiment.
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2.7 Patient selection criteria
Signed and informed consent to examine effects of
levodopa was obtained from the patients, and blood collection protocols were approved by the Graduate Studies
Committee of the University of Baghdad, Baghdad, Iraq.
Inclusion of patients was approved by and consulted with
the Alkadhumia Academic Hospital and The Renal Diseases
and Transplant Center at the Medical City Complex, Baghdad. Thus, the settings and locations where the data were
collected were in these hospital and transplant center.
Selection criteria for PKD patients followed official diagnosis criteria,[11,12] including patient age (25–45 years old),
the presence of borderline hypertension, and the number of
bilateral renal cysts based on ultrasonography diagnosis.
Selection criteria for non-PKD hypertensive (HTN) patients
included borderline essential hypertension with no secondary cause. Furthermore, they were selected to be age- and
blood pressure- matched to the PKD patients following
examination and clearance from consultant physicians. The
exclusion criteria for HTN and PKD patients were pregnancy, lactation, diabetes mellitus, myocardial infarction,
angina, renal transplantation, renal failure (or creatinine > 3
mg/dL), dialysis, and arrhythmia (according to ECG report).
None of the patients had taken any antihypertensive drugs at
the time of the study.
2.8 Clinical protocol
The clinical study was a 3-way crossover and doubleblind analysis designed to include two groups (Table 1). In
each group, patients were further divided into three subgroups randomly. Each patient received treatments three
times daily for 7 days. After a washout period of 10 days,
each patient was randomly assigned to a different subgroup
and received treatments three times daily for 7 days. After a
second washout period of 10 days, each patient was put in
Table 1. Clinical study design.
Group
Group A
(HTN patients)

Group B
(PKD patients)

Sub-group

Treatment

A1

Placebo

A2

50 mg levodopa

A3

100 mg levodopa

B1

Placebo

B2

50 mg levodopa

B3

100 mg levodopa

A 3-way crossover and double-blind analysis was designed to include two
groups, hypertensive groups without (HTN) or with polycystic kidney
disease (PKD). In each group, patients were further divided into three subgroups randomly for a corresponding treatment.

the last remaining subgroup to receive treatments three
times daily for 7 days. For each treatment, patients received
placebo, 50 mg or 100 mg levodopa capsules. A 20 mg of
domperidone capsule was taken 30 min prior to all treatments. Of note is that domperidone could block D2-like
receptor activation by levodopa and thus prevent nausea.[13,14]
The 10-day washout period was to ensure a complete removal of levodopa from the body before the next treatment.
As previously reported, the half-life of levodopa is 1–3 h
and 7–9 h for domperidone.[15]
We chose levodopa as the metabolic precursor of dopamine in borderline hypertensive patients with or without
PKD, because fenoldopam was not approved for use by the
National Committee for Drug Selection at the Ministry of
Health of Iraq. In our clinical study, domperidone was also
used as a peripheral D2 dopaminergic antagonist for two
reasons. First, it prevents some adverse effects such as nausea induced by levodopa.[13,14] Second, by blocking D2 receptors, it potentiates activation of the D1 receptors, including DR5, in the peripheral vascular system. From our clinical data (Table 2), the baseline serum creatinine level was
significantly higher in the PKD group than in the HTN
group. This suggests a progressive deterioration in renal
function in PKD, consistent with the imaging studies that
indicate the presence of renal cysts in our patients.
All physicians (Altaei QH, Alshimmari IK, Alsaidi MM
and Khammas H) from different clinics or hospitals enrolled
participations suitable to our study criteria independently,
and they administered the interventions to the participants.
The random allocation sequence of participants was generated by Kathem S and supervised by Ismail SH. Thus, neither physicians nor patients knew the subgroup classifications or treatment types. Because the steady state concentration of drug depends of its half-life, levodopa with a short
half-life would reaches steady state within two days. As
such, effects of levodopa on vasculatures should be apparent
within a week of our study, which serves as an endpoint of
our study. Blood pressure, heart rate and blood samples
were taken before treatment (baseline), two hours after the
first treatment, and two hours after the last dose on the seventh day of the treatment period. There was no follow-up
after the end of study period.
2.9 Clinical measurements
All measurements were taken after patients were in the
sitting position for at least 10 min. Blood pressure and heart
rate were measured by the physicians using mercury
sphygmomanometer and Radial pulse rate, respectively.
Blood samples (4–5 mL) were collected by venepuncture at
the clinical laboratories of the hospitals. Creatinine, urea,

http://www.jgc301.com; jgc@mail.sciencep.com | Journal of Geriatric Cardiology

Kathem SH, et al. Hypertension in PKD

70

Figure 5. Fenoldopam augmented cilia length, increased serum NO and improved blood pressure in Pkd1 mouse model (n = 3 for
each experiment; at least 35 double-blind measurements for cilia length were made in each sample. (A): Baseline blood pressure was
measured for at least 3 days in Pkd1flox/flox (wild-type) and Tie2Cre⋅Pkd1flox/flox (Pkd1) mice followed with intravenous administration of fenoldopam everyday at 1.5 mg/mL per minute for 30 min; (B): Serum NO was measured at day 3 before (control, C) and at day 9 after (fenoldopam, FD) administration of fenoldopam; (C): Cilia length was measured from the femoral arteries before C and after FD in Pkd1flox/flox
(wild-type) and Tie2Cre⋅Pkd1flox/flox mice. *P < 0.05 from the baseline values before fenoldopam treatment. NO: nitric oxide.

Levodopa, a dopaminergic agonist, was selected because it
is clinically safe for convenient oral use; however, it functions as a non-specific dopaminergic agonist for DR5 activation. Our double-blind study showed minimal effects of
moderate dosages of levodopa (50 or 100 mg) on serum NO
(Table 2). Of note, NO regulation in PKD is complicated
partly because the increase in basal levels of superoxide and
NO-induced peroxynitrite formation in smooth muscle
cells.[17] It is therefore conceivable that the NO in our patients had reacted with superoxide to form peroxynitrite.

Most importantly, the overall mean arterial pressure was
significantly decreased in patients treated with 100 mg levodopa in PKD patients (Figure 6C). Levodopa also showed
similar effect on hypertensive-only group (Figure 7). This
finding is consistent with our cell culture in vitro and mouse
in vivo studies showing that activating DR5 can also
increase cilia length and sensitivity to produce NO in normal wild-type control group. It is probable that our hypertensive-only group had a constricted vascular tone that
would also be beneficial with dopamine treatment.
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Figure 6. Serum levels of NO, ADMA and effects of levodopa on hypertensive-only and hypertensive-PKD patients. (A): Compared
to HTN patients, baseline serum NO was significantly lower in hypertensive patients with PKD; (B): Compared to HTN patients, baseline
serum ADMA was significantly higher in PKD patients; (C): Blood pressure was measured at baseline and 7 days after placebo or levodopa
treatment. Levadopa is effective to improve mean arterial pressure in both HTN and PKD patients. *P < 0.05 between HTN and PKD groups
(in A and B), or between different treatments and corresponding baseline groups (in C). ADMA: asymmetric dimethylarginine; HTN: hypertensive-only; NO: nitric oxide; PKD: polycystic kidney disease.

4 Discussion

Figure 7. Levodopa decreases the overall mean arterial
pressure. Blood pressure was measured at baseline, 2-h and 7 days
after placebo or levodopa treatment (placebo vs. 50 mg vs. 100 mg).
Levadopa was effective to improve mean arterial pressure in both
HTN and hypertensive-PKD patients. *P < 0.05 compared to corresponding baseline groups. HTN: hypertensive-only; PKD: polycystic kidney disease.

In the present study, our basic science studies indicated
that activation of ciliary DR5 with DR5-specific agonist
(fenoldopam) increases NO biosynthesis transiently. More
importantly, DR5 activation increased cilia length, partially
rescued mechanosensitivity of PKD endothelial cells to fluid-shear stress, and thereby decreased the overall mean arterial pressure. In the clinical study, we showed that hypertensive PKD patients had a significantly lower baseline level of
NO compared to hypertensive-only patients. More importantly, modest dosage of levodopa at 50 mg or 100 mg decreased the mean arterial blood pressure in the PKD group.
We also confirm that the baseline level of ADMA, an endogenous inhibitor for eNOS and a marker for endothelial
dysfunction, is significantly higher in the PKD group compared to the hypertensive-only group.
Consistent with the in vitro study, our in vivo data sug-

http://www.jgc301.com; jgc@mail.sciencep.com | Journal of Geriatric Cardiology

Kathem SH, et al. Hypertension in PKD

72

gest that fenoldopam could extend the length of primary
cilia and induce a greater NO production. These would ultimately decrease the overall mean arterial pressure in Pkd1
mouse model. Of note is that fenoldopam at 1.5 mg/kg
showed a trend of lower blood pressure in wild-type mice,
albeit this decrease was not statistically significant. One
possible explanation is that the baseline vascular tone in
wild-type mice was already low. As a result, no significant
effect of increasing NO on vasodilation was observed. It is
worth mentioning that the baseline serum levels of NO were
significantly lower in Pkd1 mice compared to wild-type.
ADMA acting as a physiological inhibitor of NO biosynthesis has been used as a marker for endothelial function
in the clinical setting.[18,19] Plasma ADMA levels are highly
correlated with the severity of endothelial dysfunction, and
high ADMA level further impairs blood flow and accelerates atherogenesis through endothelial dysfunction.[20] Thus,
our clinical data indicated that compared to the hypertensive-only group, the PKD group had an abnormality in
regulating NO biosynthesis. This is consistent with our previous study indicating that vascular-lining endothelia from
patients with PKD are dysfunctional due to their non-responsiveness to flow-induce NO biosynthesis.[5]
In particular, the mechanism of dopamine receptor, especially DR5, in blood pressure regulation still remains unknown. Although it has been propose that peripheral dopaminergic activation increases renal blood flow,[21] we propose that this vasodilation effect of dopamine on renal arteries acts by sensitizing primary cilia function. In our study,
levodopa had a minimal effect on individual systolic or diastolic blood pressure (Table 2). Without doubt, a more specific dopaminergic agonist for DR5 may be more suitable
for therapeutic management of hypertensive PKD patients.
Unfortunately, fenoldopam was not approved for use in our
study. We did not seek for a higher dosage of levodopa due
to the safety concerns in our patients. Nonetheless, our clinical study sheds light on the possibility for cilia-targeted
therapy in PKD patients and possibly in general hypertensive patients.
In summary, our results show that fenoldopam increased
cilia length, which further enhanced the mechanosensory
function of cilia in NO biosynthesis. Results from a less
complex in vivo rodent system with endothelial cilia dysfunction support the idea that a DR5-cilia-NO axis plays an
important role in regulating blood pressure in PKD. In a
more complex clinical setting, dopaminergic receptor activation showed a potential therapeutic benefit on overall
arterial blood pressure. Together, our studies serve as a
proof of principle for targeted-clinical therapy on primary
cilia as a novel mechanism to modulate the progression of a
ciliopathy.
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